Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2014-06-25 Audit Report / Informat…
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Jahresabschluss 2013
Audit Report / Information Classification · 99% confidence The document is titled "Bericht über die Prüfung des JAHRESABSCHLUSSES zum 31. Dezember 2013" (Report on the Audit of the ANNUAL FINANCIAL STATEMENTS as of December 31, 2013). It contains a detailed table of contents listing sections like 'Prüfungsauftrag' (Audit Mandate), 'Stellungnahme zur Lagebeurteilung des Vorstandes' (Statement on the Management's Assessment of the Situation), and explicitly references the 'Jahresabschluss' (Annual Financial Statements) and 'Lagebericht' (Management Report) in the annexes and body. The content is clearly the formal report issued by an auditor regarding the company's annual financial statements for the fiscal year ending December 31, 2013. This aligns perfectly with the definition of an Audit Report/Information (AR), which covers standalone audit reports, distinct from the full Annual Report (10-K) itself, although it is intrinsically linked to the annual reporting cycle. FY 2013
2014-06-25 German
Formycon AG startet mit der Entwicklung des dritten Produktes und bestatigt Vorreiterrolle bei der sogenannten Dritten Welle der Biosimilars
Regulatory Filings Classification · 100% confidence The document is a press release dated June 16, 2014, issued by Formycon AG via DGAP (a corporate news distribution service). The content announces a business development: the start of development for a third product (a biosimilar) and commentary on the company's strategic positioning relative to industry trends (the 'Third Wave' of biosimilars). This type of announcement, focusing on strategic business updates, product pipeline progress, and management commentary outside of mandated financial reporting periods (like 10-K or IR), typically falls under general corporate news or investor relations updates. Since it is not a formal financial report (10-K, IR, ER), a specific regulatory filing (like DIRS, DIV, SHA), or a transcript (CT), it is best classified as a general Regulatory Filing (RNS) as it is a formal announcement distributed through official channels, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate general category for non-standard, material corporate news distribution.
2014-06-16 German
Formycon AG announces financial results of fiscal year 2013 and first quarter results of fiscal year 2014
Earnings Release Classification · 100% confidence The document is titled "Formycon AG announces financial results of fiscal year 2013 and first quarter results of fiscal year 2014" and contains key financial metrics (revenue, EBITDA, net income) for both the full fiscal year 2013 and the first quarter of 2014. This content structure, focusing on the immediate release of period-specific financial performance highlights, strongly indicates an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), as it is presented as a news announcement disseminated via DGAP, focusing on the 'key highlights' rather than the full statutory filing. Q1 2014
2014-05-12 English
Formycon AG: Strong partner increases marketing potential for the first biosimilar development project
M&A Activity Classification · 99% confidence The document is a press release dated March 25, 2014, announcing a strategic partnership (joint venture) between Formycon AG and Polpharma regarding a biosimilar development project (FYB201). It details business developments, licensing agreements, and strategic positioning, rather than reporting periodic financial results (ER/IR), providing formal audit opinions (AR), or announcing executive changes (MANG). Since it is a general corporate announcement about a business development that doesn't fit the highly specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general Regulatory Filings/Announcements category, which is RNS, as it is disseminated via DGAP (a service for regulatory announcements and corporate news).
2014-03-25 English
Formycon AG appoints top US pharmaceuticals manager Bernhard Hampl to the Advisory Board
Board/Management Information Classification · 100% confidence The document is a press release dated March 13, 2014, announcing that Formycon AG has appointed a new member, Dr. Bernhard Hampl, to its Advisory Board. The key phrase is "Change of Personnel." This type of announcement, detailing changes in the company's board or senior management, directly corresponds to the definition for Board/Management Information (MANG). It is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a director's dealing (DIRS).
2014-03-13 English
Datum:03.01.2014
Annual Report Classification · 100% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for Formycon AG for the fiscal year 2012. It contains a balance sheet (Bilanz), notes to the financial statements (Anhang), a cash flow statement (Kapitalflussrechnung), and details on management and subsidiaries. As it represents the comprehensive annual financial reporting for the company, it is classified as an Annual Report (10-K). FY 2012
2014-01-03 German

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.